2-188999318-C-G
Variant summary
Our verdict is Benign. Variant got -15 ACMG points: 1P and 16B. PP2BP4_StrongBP6_Very_StrongBS1
The NM_000090.4(COL3A1):āc.2056C>Gā(p.Pro686Ala) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000245 in 1,589,350 control chromosomes in the GnomAD database, with no homozygous occurrence. In-silico tool predicts a benign outcome for this variant. 16/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (ā ā ).
Frequency
Consequence
NM_000090.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -15 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
COL3A1 | NM_000090.4 | c.2056C>G | p.Pro686Ala | missense_variant | 30/51 | ENST00000304636.9 | NP_000081.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
COL3A1 | ENST00000304636.9 | c.2056C>G | p.Pro686Ala | missense_variant | 30/51 | 1 | NM_000090.4 | ENSP00000304408.4 | ||
COL3A1 | ENST00000450867.2 | c.1957C>G | p.Pro653Ala | missense_variant | 29/50 | 1 | ENSP00000415346.2 |
Frequencies
GnomAD3 genomes AF: 0.00133 AC: 203AN: 152158Hom.: 0 Cov.: 32
GnomAD3 exomes AF: 0.000344 AC: 71AN: 206110Hom.: 0 AF XY: 0.000298 AC XY: 33AN XY: 110726
GnomAD4 exome AF: 0.000130 AC: 187AN: 1437074Hom.: 0 Cov.: 32 AF XY: 0.000112 AC XY: 80AN XY: 712496
GnomAD4 genome AF: 0.00133 AC: 203AN: 152276Hom.: 0 Cov.: 32 AF XY: 0.00128 AC XY: 95AN XY: 74464
ClinVar
Submissions by phenotype
Familial thoracic aortic aneurysm and aortic dissection Benign:3
Benign, criteria provided, single submitter | clinical testing | Color Diagnostics, LLC DBA Color Health | Nov 16, 2018 | - - |
Likely benign, criteria provided, single submitter | clinical testing | Ambry Genetics | Mar 19, 2018 | This alteration is classified as likely benign based on a combination of the following: seen in unaffected individuals, population frequency, intact protein function, lack of segregation with disease, co-occurrence, RNA analysis, in silico models, amino acid conservation, lack of disease association in case-control studies, and/or the mechanism of disease or impacted region is inconsistent with a known cause of pathogenicity. - |
Benign, criteria provided, single submitter | clinical testing | CHEO Genetics Diagnostic Laboratory, Children's Hospital of Eastern Ontario | Dec 30, 2021 | - - |
not provided Benign:3
Likely benign, criteria provided, single submitter | clinical testing | ARUP Laboratories, Molecular Genetics and Genomics, ARUP Laboratories | Jan 29, 2021 | - - |
Benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Aug 22, 2016 | Variant summary: The COL3A1 c.2056C>G (p.Pro686Ala) variant causes a missense change involving a non-conserved nucleotide with 2/3 in silico tools (SNPs&GO and MutationTaster not captured here due to low relability index and p-value, respectively) predict a "benign" outcome, although these predictions have yet to be functionally assessed. The variant of interest was observed in the large, broad control population, ExAC, with an allele frequency of 33/36436 (1/1104), predominantly in the African cohort, 33/3964 (1/120), which significantly exceeds the estimated maximal expected allele frequency for a pathogenic COL3A1 variant of 1/769230. Therefore, suggesting the variant of interest is a common polymorphism found in population(s) of African origin. The variant of interest, to our knowledge, has not been reported in affected individuals via publications, while one reputable clinical laboratory cites the variant as "likely benign." Therefore, the variant of interest has been classified as Benign. - |
Likely benign, criteria provided, single submitter | clinical testing | GeneDx | Aug 04, 2021 | - - |
Ehlers-Danlos syndrome, type 4 Benign:1
Benign, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Jan 29, 2024 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at